Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic vasculitis: still a challenging disease.

Irina Buhaescu1, Adrian Covic, Jeremy Levy

  • 1Dialysis and Renal Transplantation Center, Parhon University Hospital, Iasi, Romania. irinab99@yahoo.com

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|August 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2024
Same author

The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration.

Kidney international·2024
Same author

Proximal tubule hypertrophy and hyperfunction: a novel pathophysiological feature in disease states.

Clinical kidney journal·2024
Same author

Exploring the nexus: The place of kidney diseases within the cardiovascular-kidney-metabolic syndrome spectrum.

European journal of internal medicine·2024
Same author

Metabolically healthy obesity and chronic kidney disease risk: exploring the dynamics.

Panminerva medica·2024
Same author

Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2024
Same journal

Hemophagocytic Lymphohistiocytosis and Fibroblast Growth Factor 23 (FGF23)-Induced Hypophosphatemia.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Kidney Transplantation Post-Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Multiple Myeloma.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Palliative Dialysis: Putting the Person First in Dialysis Care.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Metabolic Acidosis and Progression of CKD: Current Guidelines and Considerations.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same journal

Pathophysiology of Ketoacidosis: Core Curriculum 2026.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
See all related articles

Current systemic vasculitis treatments are effective but toxic. New therapies like rituximab and infliximab, alongside refined use of cyclophosphamide and azathioprine, aim to improve outcomes and reduce toxicity in vasculitis management.

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Pharmacology

Background:

  • Systemic vasculitis treatments offer high efficacy but significant toxicity.
  • Optimal therapeutic strategies for these life-threatening conditions remain under investigation.
  • Advances in understanding vasculitis pathogenesis drive the development of targeted therapies.

Purpose of the Study:

  • To review recent data on managing systemic antineutrophil cytoplasmic antibody-associated vasculitis.
  • To emphasize strategies for improving long-term outcomes and reducing treatment toxicity.
  • To minimize the risk of relapse in patients with systemic vasculitis.

Main Methods:

  • Review of recent randomized prospective clinical trials.
  • Analysis of data on conventional treatments (cyclophosphamide, azathioprine, plasma exchange).

Related Experiment Videos

  • Evaluation of emerging therapies including mycophenolate, rituximab, infliximab, and etanercept.

    • Main Results:

    • Evidence supports short-duration cyclophosphamide therapy (3 months).
    • Long-term maintenance therapy (e.g., azathioprine) is crucial for preventing relapse.
    • Risk stratification for relapse-prone patients is becoming clearer.

    Conclusions:

    • Newer agents like rituximab and cytokine inhibitors show promise for targeted vasculitis treatment.
    • Optimizing conventional therapy duration and maintenance is key to managing vasculitis.
    • Balancing treatment efficacy, toxicity, and relapse risk is essential for improved patient outcomes.